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 In this review article, we will explore some of the contem-
porary methods for predicting sudden cardiac death (SCD). 
These include experimental methods yet to be adopted in the 
clinical setting, and methods that have been extrapolated 
from observational data in those with a history of SCD. We 
will discuss how these relate to the different aetiologies and 
disease processes. We will also explore how these may be used 
in the clinical setting to decide on management. 
 Introduction 
 Determining an individual’s risk of sudden death from life-
threatening cardiac arrhythmias (sudden cardiac death (SCD)) 
remains a challenging task. An understanding of high-risk 
features allows clinicians to identify those who will benefit most 
from risk-modifying therapies or other forms of treatment. 
 Secondary prevention in patients following a life-threatening 
arrhythmia can significantly reduce cardiovascular event rates. 
However, primary prevention in patients with acquired cardiac 
disease still relies heavily on impairment of left ventricular 
function. 1 Most individuals with inherited cardiac conditions 
(ICCs) may display evidence of the condition but remain 
asymptomatic, yet the risk of SCD in these individuals is of 
paramount concern, especially in the absence of structural 
heart disease that may carry its own mortality. Large-scale 
evidence-based studies for clinicians to draw on are lacking. 
 Furthermore, the only definitive treatment currently available 
across all acquired and genetic disease entities in the prevention 
of SCD in high-risk patients is the implantable cardioverter 
defibrillator (ICD). This, however, has an enormous physical 
and psychological impact on the recipient and the decision to 
implant must be well thought out and justified robustly with 
objective evidence of risk. 
 Therefore, a number of methods to risk stratify these 
individuals are employed that may be specific to the disease 
process, whereas others may be of use across a spectrum of 
disease processes, acquired and genetic. 
 In this update review article, we will concentrate largely on 
recent developments in the assessment of risk of SCD and 
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discuss the prognostic impact these may have. While there is 
a focus on ICCs as exemplars of these techniques we will also 
reflect on the role of these approaches in acquired heart disease. 
Some of these methods are yet to withstand robust clinical 
validation and are of experimental and research value, whereas 
others are of potential use in current clinical practice. For 
practical utility most are non-invasive, although we also explore 
the role for invasive electrophysiological studies. 
 Integrating old risk factors 
 A novel risk calculator based on existing established and readily 
available risk factors offers one approach for extracting greater 
predictive accuracy. This has been undertaken for hypertrophic 
cardiomyopathy (HCM) and adopted early by the European 
Society of Cardiology. 2 
 Electrocardiogram markers of ventricular 
repolarisation 
 The QT interval is the commonly used measure of ventricular 
repolarisation time; prolongation of the QT interval is 
associated with an increased risk of SCD. However, in most 
population-based studies, no consistent association has 
been found between QT interval prolongation and total or 
cardiovascular mortality, thus limiting its use as a clinical 
marker of risk. 3 A number of other electrocardiogram (ECG) 
markers of ventricular repolarisation have been suggested as 
predictors for the development of ventricular arrhythmias in a 
variety of disease processes. 4 
 Tpeak-end interval 
 More recently, however, the Tpeak-end (Tp-end) interval 
interval, the time between the peak and the end of the T wave 
proposed to represent transmural dispersion of ventricular 
repolarisation, has been found to predict the risk of malignant 
cardiac arrhythmias in a number of clinical settings (Fig 1). 5 
In 235 patients with Brugada syndrome (BrS), Tp-end was 
significantly increased in those presenting with malignant 
arrhythmias or syncope compared with asymptomatic 
carriers. 6 
 In addition, both Tpeak-end and Tpeak-end/QT ratio have 
been examined during acute ST elevation myocardial infarction 
(STEMI ). Tp-end was found to be signifi cantly prolonged in 
STEMI compared with healthy individuals. A Tpeak-end >0.1 
and Tpeak-end/QT ratio >0.3 predict malignant ventricular 
arrhythmias within 24 hours of STEMI. 7 
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 Microvolt T-wave alternans 
 Another measure, T-wave alternans, is the beat-to-beat variation 
in the T-wave amplitude, and is an indicator of instability of 
repolarisation associated with impending arrhythmic risk 
described initially in the long-QT syndrome 8 but applicable to 
other disorders. Microvolt T-wave alternans (MTWA) measures 
T-wave alternans that are undetectable visually. 
 In the Alternans Before Cardioverter Defibrillator (ABCD) 
study, 9 MTWA was compared to invasive electrophysiological 
testing (EPS), in its ability to predict the risk of ventricle 
dysrhythmia in those with ischaemic cardiomyopathy 
(left ventricular ejection fraction (LVEF) <40%). Subjects 
underwent insertion of an ICD if either parameter was positive. 
At 1 year, positive and negative predictive values for MTWA (9 
and 95%, respectively) were comparable to EPS (11 and 95%, 
respectively). 
 The REFINE trial demonstrated increased event rates in 
patients with MTWA in the sub-acute phase post myocardial 
infarction (MI). 10 Merchant  et al 11 studied over 2,800 
patients without a history of cardiac arrest or ventricular 
arrhythmias. MTWA was positive in 30%, negative in 56% 
and indeterminate in 14%. In patients with LVEF <35% 
and negative MTWA, annual event rates were low at 0.9%, 
while event rates were significantly higher in the positive and 
indeterminate groups, 4.0 and 4.6%, respectively. Patients with 
an LVEF of >35% and a positive MTWA test were at increased 
risk of SCD: 3.0% compared with 0.3% in MTWA negative and 
indeterminate groups. 
 While intriguing, MTWA and Tp-end remain to be validated 
in routine clinical use as a number of limitations exist. For 
example, manual methods of measuring T-wave amplitudes and 
durations are inaccurate and, thus, automated methods have 
been developed; however, the computerised methods differ 
between manufacturer and this is likely to produce variability 
in reporting. Additionally, the range of normal values for Tp-
end and Tp-end/QT, which is likely to vary greatly, are yet to be 
robustly defined or explored in normal subjects. 
 Large prospective studies are required to evaluate the 
usefulness of these methods in different clinical entities given 
that the annual event rate can be extremely low. 
 Other potential measures of repolarisation include QT-
interval dispersion, QT variability and QRST angle. As yet, 
none have been implemented in clinical practice because of a 
lack of robust validation. A review article by Tikkanen  et al 12 
and work by Picarillo  et al 13 explore these additional markers in 
more detail. 
 Early repolarisation 
 Early repolarisation (ER) is currently defined as elevation of the 
QRS–ST junction (J point) in at least two leads in the inferior 
or lateral distribution. Elevation must be at least 1 mm (0.1 mV) 
above the baseline level (Fig 2a). This may manifest as slurring 
or notching of the QRS. It may be present in up to 15% of the 
population with a higher prevalence in young men, athletes and 
those of African descent. 14 
 Previously, ER was thought to be a benign feature on the 12-
lead ECG but was linked to idiopathic ventricular fibrillation 
in 2008 by Haissaguerre  et al. In 206 survivors of cardiac arrest 
from ventricular fibrillation, ER was demonstrated in 31%. 
Additionally, recurrent VF was more common in those with 
ER. 15 
 Further work by  Tikkanen et al 16 looked at the long-term 
outcome associated with ER in a cohort of over 10,000 middle-
aged Finnish subjects with a mean follow-up of 30±11 years. 
 Fig 1.  Tpeak – Tend interval (Tp -end ). 
Key points
Clinical symptoms remain the most consistent means of 
determining risk of future events.
In the absence of symptoms, identiﬁcation of high-risk features 
is paramount in order to determine those that might beneﬁt 
from implantable cardiac deﬁbrillator therapy.
With annual event rates being low in those with inherited 
cardiac disease, it is difﬁcult to identify non-clinical markers that 
sufﬁciently and consistently separate high- and low-risk groups.
Novel electrocardiographic risk predictors aim to identify subtle 
abnormalities in repolarisation and depolarisation. However, 
with varying levels of sensitivity and speciﬁcity, consistent 
incorporation into clinical practice is difﬁcult.
A risk prediction model that incorporates multiple parameters, 
including electrocardiogram data, structural information and 
genetics that can be used across a variety of diseases is likely to 
be the ideal model of the future.
KEYWORDS: Sudden cardiac death, ventricular arrhythmia, 
inherited heart disease and ischaemic heart disease ■
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ER was demonstrated in 5.8%. Inferior J-point elevation of 
>0.1 mV was associated with an increase in risk of cardiac 
death (relative risk (RR) 1.28; p=0.03). J-point elevation >0.2 
mV had a markedly elevated risk of cardiac death (RR 2.98; 
p<0.001) and from arrhythmia (RR 2.92; p=0.01). The Finnish 
group further stratified ER risk according to ST-segment 
morphology: 17 upsloping ascending (Fig  2B ) and horizontal 
descending (Fig  2C ). The former appeared to have a benign 
association while the latter showed association with arrhythmic 
risk (hazard ratio (HR) 1.43; 95% confidence interval 1.05–1.94). 
The clinical relevance of ER in the general population is low; 
however, given the high prevalence and low absolute risk, it 
should not be used as a clinical marker of risk in this context. 14 
 In patients with an existing substrate for malignant 
arrhythmia, ER may be of greater clinical utility. In BrS for 
example, one study observed that 10–15% of patients had 
infero-lateral ER accompanied by an 11-fold increase in risk 
of VF. 18 In addition, Chan  et al 19 investigated ER in a cohort of 
59 arrhythmogenic right ventricular cardiomyopathy (ARVC) 
patients, 64% demonstrating ER in the inferior leads who had 
a higher incidence of VF or aborted SCD. In acute STEMI, ER 
has been found to be associated with a significant increase in 
risk of ventricular tachyarrhythmia in the acute post infarction 
phase (<72 hours), irrespective of left ventricular function and 
level of cardiac enzyme rise. 20,21 In patients with known chronic 
coronary artery disease, ventricular arrhythmia has been found 
to be more common in those with inferior early repolarisation; 
additionally, the presence of associated notching was also 
strongly associated with risk. 22 Further validation is required 
before ER can be employed in this setting. 
 ECG markers of ventricular depolarisation 
 The QRS duration as a readily available marker of ventricular 
depolarisation has also been associated with the risk of SCD in 
the general population. 23,24 Patients with prior MI and/or heart 
failure with a QRS duration >120 ms and/or left bundle branch 
block may be indicated for cardiac resynchronisation therapy 
alongside ICD therapy depending on symptoms and ejection 
fraction. 1 The following other markers have been explored for 
additive value. 
 Late ventricular potentials and the signal averaged ECG 
 Late ventricular potentials are abnormal low-amplitude 
signals in the terminal portion of the QRS complex reflecting 
delayed depolarisation in the ventricles. This suggests the 
presence of potential substrates for ventricular arrhythmia. 
Late potentials cannot, however, be visualised on a standard 
ECG recording requiring a signal averaged ECG (SAECG) 
being acquired over a prolonged period (7–10 minutes). 
During this period, a number of QRS complexes are collected 
from orthogonal ECG leads ( x, y and  z ) with wide-frequency 
filters and averaged to reduce interference due to artefact. 
These signals can then be processed using ECG analysing 
software (Fig 3). 
 Fig 2.  A – Typical J point eleva-
tion; B – upsloping ascending 
with notching (arrowed); C – 
horizontal descending. 
 Fig 3.  Signal-averaged electrocardiogram. LP = late potentials; QRSd = 
total QRS duration; RMS = root mean square in the terminal 40 ms of QRS. 
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 The presence of late potentials is a strong predictor of 
ventricular arrhythmias in a number of conditions, including 
post-MI, dilated cardiomyopathy and arrhythmogenic 
cardiomyopathy, 25 and is a diagnostic tool in arrhythmogenic 
right ventricular cardiomyopathy. 26 A number of small 
contemporary studies have attempted to evaluate the use of 
the SAECG in the BrS. There is an increased risk of ventricular 
fibrillation in those patients in whom late potentials are 
detected, although an old meta-analysis has suggested that in 
multivariable analysis the association may be lost. 27 
 Unfortunately, while the SAECG is a non-invasive, 
quantitative tool that can be repeated over time, it requires a 
specialist ECG machine or plug-in that most centres do not use 
routinely. It therefore remains an underutilised tool. 
 QRS fragmentation 
 Fragmentation of the QRS complex (f-QRS) refers to slurring 
and notching within the QRS morphology and has been 
correlated with the presence of myocardial scar and fibrosis 
(Figs 4 and 5). 28  f-QRS has been demonstrated to predict 
cardiac arrhythmias in conditions such as ARVC, acute MI, 
dilated cardiomyopathy and infiltrative conditions such as 
sarcoidosis. 28 
 Fig 4.  Notching within the S wave. 
 The PRELUDE study 29 evaluated 308 patients with BrS 
without a history of cardiac arrest. This concluded that patients 
with f-QRS had a nine times greater risk of developing VF. 
Tokioka  et al 30 then examined the f-QRS and ER for predicting 
outcomes in BrS patients. They demonstrated that presence of 
both ER and f-QRS significantly increased the risks of cardiac 
arrhythmias compared with patients with f-QRS alone or 
without either abnormality. The event rates in patients with 
neither abnormality were extremely low. At this time, guidelines 
on prophylactic device therapy do not indicate f-QRS or ER as 
accepted markers for risk assessment. 31 They may, however, offer 
value in risk stratification on a case-by-case basis. 
 Markers of autonomic dysfunction 
 Heart rate variability and turbulence 
 Heart rate variability (HRV) is the beat-to-beat variation 
in heart rate, this is influenced by autonomic effects on the 
sinoatrial node. The changes in the heart rate in response 
to a premature ventricular complex is termed the heart rate 
turbulence (HRT ); there is a baroreflex-mediated influence 
on the sinoatrial node which results in a temporary increase 
in heart rate followed by a decrease back to the baseline. 
Impaired autonomic function, as measured by HRV and 
HRT, has been proven to predict adverse outcomes in clinical 
settings, including post-MI 32,33 and congestive cardiac failure. 34 
However, in a large meta-analysis of risk predictors in the non-
ischemic dilated cardiomyopathy group, it was demonstrated 
that the autonomic factors were not significant predictors 
of arrhythmic outcome, but had a high negative predictive 
accuracy 35 . Much like MTWA, the limitations in uptake by 
Holter manufacturers and variable software packages have 
resulted in limited use except by specialist centers. 
 Invasive programmed electrical stimulation 
 Electrophysiological study for investigating the risk of sudden 
death was first used to test drug suppression of ventricular 
arrhythmias in cardiac arrest survivors. It was then utilised 
 Fig 5.  Widespread QRS frag-
mentation in a patient with 
Brugada syndrome. 
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in risk stratification of post-infarct patients prior to ICD 
implantation. 36 It quickly became apparent that inducibility of 
ventricular tachycardia was less effective a marker than ejection 
fraction alone. 37,38 Inducibility of ventricular fibrillation was 
always thought to be non-specific and clinically unhelpful, 
especially in a structurally normal heart. 39 Thus, while it has 
fallen out of fashion in other arenas, its role in prediction of 
future events in BrS is a topic of current debate. A variety of 
protocols have been employed involving stimulation at the 
right ventricular apex with or without additional pacing at the 
outflow tract and the use of a maximum of two or three extra 
stimuli with a minimum pacing interval of 200 ms. A positive 
test has been defined as a sustained ventricular arrhythmia. 
 The Brugada brothers first proposed that inducibility of 
programmed electrical stimulation (PES) could predict SCD 
irrespective of presenting symptoms and ECG. 40–42 Despite 
these findings, subsequent large multi-centered analysis failed 
to replicate these associations. The FINGER study, 43 the largest 
European registry of BrS with over 1,029 consecutive patients, 
demonstrated in a multivariate analysis that inducibility was 
not an independent predictor of cardiac events. The PRELUDE 
study 29 found no significant differences between those with 
inducible ventricular arrhythmia and those without. It did, 
however, highlight the value of QRS fragmentation and the 
ventricular effective refractory period (VERP) as two important 
risk predictors. VERP is the maximum pacing interval between 
extra stimuli at which the ventricle is refractory. A VERP <200 
ms had a greater sensitivity and specificity at predicting events 
than inducibility, and was associated with a HR of 3.9. Despite 
the observed differences in the reliability of inducibility, a key 
factor in all studies is the link between the presence of high-risk 
clinical features and future events; with a spontaneous type-1 
pattern and syncope being the stand out clinical determinants. 
Meta-analyses by Letsas  et al 44 and Sroubeck  et al 45 confirm 
these associations. 
 Imaging 
 Cardiac magnetic resonance imaging 
 Myocardial fibrosis and scar is a key substrate for ventricular 
arrhythmias regardless of aetiology. Contrast magnetic 
resonance imaging (MRI) using gadolinium is the gold 
standard imaging modality to identify the presence of fibrosis 
by detection of late gadolinium enhancement (LGE). 46 Iles 
 et al 47 prospectively evaluated a cohort of 103 patients with non-
ischaemic or ischaemic cardiomyopathy eligible for primary 
prevention ICD. Among non-ischaemic group, the presence of 
fibrosis was associated with arrhythmic events during follow-up 
in one-third, whereas non-ischaemic patients without fibrosis 
remained arrhythmia free. While LGE is an independent risk 
factor for all-cause mortality, those with evidence of diffuse 
or mid-wall fibrosis have higher risk. 48 The finding of LGE in 
HCM patients also appears to associate with risk of SCD and 
offers an additional risk factor to be taken into account in 
patient management. 49 
 ECG mapping 
 ECG imaging is a non-invasive imaging modality, which 
reconstructs epicardial signals using body surface electrodes, 
mapping cardiac electrical excitation in relation to the heart’s 
anatomy derived from high-resolution thoracic computerised 
tomography or MRI. This produces a digital image of epicardial 
electrograms and activation/repolarisation sequences. It has 
been proposed that ECG imaging could be used to identify 
repolarisation abnormalities, fractionated signals and low-
amplitude electrograms that are potential substrates for 
malignant arrhythmias. 50 This could be applicable to those 
with cardiomyopathy, post-MI or inherited cardiac conditions. 
There may also be a role in supporting ventricular tachycardia 
ablation. 51 As yet, the role of ECG imaging in risk evaluation 
remains in research but it appears to offer a highly accurate, 
multi-dimensional assessment of arrhythmia characterisation 
and localisation, which sets it apart from other non-invasive 
ECG markers. 
 Biomarkers and genomics 
 Biomarkers for inflammation, neurohumoral activation and 
cardiac injury have been studied in patients with primary 
prevention ICDs to predict appropriate shocks (a surrogate 
marker for SCD) and all-cause mortality. 52 PROSE-ICD 52 
investigated five potential biomarkers; C-reactive protein, 
interleukin-6, tumour necrosis factor-α receptor II, pro-brain 
natriuretic peptide (pro-BNP) and cardiac troponin T. All 
markers were associated with a significant increase in all-
cause mortality but only interleukin-6 had an association with 
predicting appropriate shock therapy. 
 Levin  et al 53 demonstrated that the risk of ventricular 
arrhythmias was significantly higher in those with elevated 
N-terminal-proBNP (NT-proBNP) and BNP levels after 
adjustment for other risk factors. Whether this is purely a 
marker of suboptimal medical therapy or whether this can be 
used to aid ICD insertion, needs further evaluation. 
 Genetic testing in the setting of cardiac genetic disease, such 
as the long-QT syndrome and HCM, is clinically useful in 
predicting risk of sudden death in suspicious cases and relatives 
of index cases.  54 While genotype alone has a minimal role in 
risk stratification at present, the presence of multiple mutations 
is associated with higher risk. 55 
 The risk of SCD from acquired cardiac disease also has a 
genetic influence. In the AGNES study, cardiac arrest due 
to ventricular fibrillation following a first acute STEMI was 
three-fold more common in those with a family history for SCD 
than those without. 56 Genome-wide studies associated this risk 
with the common genetic variant rs2824292, 57 located close 
to a gene (CXADR) encoding for the coxsackie virus receptor. 
This appears to alter cardiac conduction in the presence of 
ischaemia. 56,57 Multiple common genetic variants and their 
additive effects may also predict the risk of SCD. 58 
 In general, however, genomic risk markers and biomarkers 
offer small increments in absolute risk level and the former 
are only applicable to specific ethnic populations. Their value 
when integrated with other clinical risk markers remains to be 
explored and their role is in research at this time. 
 Conclusion 
 Use of high-risk features enabling clinicians to identify 
those whose benefit from ICD therapy may outweigh the 
associated risks from the procedure and future device-related 
complications. However, current National Institute for Health 
CMJv16n3-Bode.indd   287 25/04/16   8:40 PM
CME Cardiology
288 © Royal College of Physicians 2016. All rights reserved.
and Care Excellence guidelines 1 for ICD therapy are limited by 
conventional risk stratifiers. 
 Unfortunately, many of the markers identified in this 
review (and there are many others too numerous to include) 
are limited in their adoption in routine clinical activity by a 
number of factors: the need for additional equipment and/
or expense with variation in manufacturer specifications and 
software; limited robust validation in clinical settings; and 
small independent incremental value in risk assessment. 
 Regardless of the underlying disease, the most difficult 
group to stratify are those who are asymptomatic. Parameters 
extrapolated from survivors of cardiac arrest and an 
understanding of the natural progression of the disease type 
support risk stratification in the asymptomatic group, especially 
in rarer disorders. However, with some disease types having low 
annual events rates, BrS for example, it is difficult to identify 
non-clinical factors that separate high- and low-risk groups. 
 The time is now ripe for major prospective multimodality 
studies assessing novel risk markers in the general population 
and patients with coronary artery disease and heart failure. 
Multicentre registries with deep phenotyping of rare disorders 
will be required to establish new accurate management 
protocols. Only then will risk prediction be optimised for the 
individual and ICD therapy directed more accurately. ■
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